Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates



  Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates

  PR Newswire

  NEW YORK, February 7, 2013

NEW YORK, February 7, 2013 /PRNewswire/ --

Zynga reported fourth-quarter earnings and sales late Tuesday, revealing that
the Company earned 1 cent per share, or $6.9 million, on sales of $311 million
last quarter. Analysts polled by Thomson Reuters expected a loss of 3 cents
per share and $212 million in revenue. The Company's tally of daily active
users rose to 56 million in the fourth quarter of 2012 meaning 2 million new
daily active users were added in the last year.

Whether bull or bear The Stock Freak has got you covered! Sign up to receive
our free newsletters and stay up to date with stocks on the run.
http://www.TheStockFreak.com    

Elan Corporation, plc (NYSE: ELN) - ELN shares closed down 10.23% yesterday at
$9.39. The stock was one of the biggest losers on the NYSE on Wednesday even
though the Company released strong fourth quarter and full-year 2012 financial
results yesterday. Full Year 2012 guidance was met; Pro-forma Revenues up 13%;
Adjusted EBITDA was up 31%. Elan Corporation, plc operates as a
neuroscience-based biotechnology company in the United States, Ireland, and
internationally. It engages in research, development, and commercial
activities primarily in the areas of Alzheimer's disease, Parkinson's disease,
and multiple sclerosis (MS). The company offers Tysabri, an alpha-4 integrin
inhibitor primarily for the treatment of MS.  Biogen Idec Inc. has agreed to
buy partner Elan Corp's stake in the Tysabri multiple sclerosis medicine for
$3.25 billion in cash plus future royalties. The number of patients taking
Tysabri grew by 12% in 2012. At 63,059,803 shares traded yesterday, volume was
roughly thirty times higher than average.

BlackBerry (Nasdaq: BBRY) - shares of BlackBerry closed in the green for the 5
^th trading day in a row yesterday. The stock modestly closed up 0.19% on
Wednesday on volume almost double the stock's average. Trading volume
yesterday was 100,212,704 shares. BlackBerry has been one of the most active
stocks on the Nasdaq recently. The Company launched two new phones last week,
the Z10 and the Q10, both running a new operating system called BB10.
BlackBerry said on Wednesday that the Canadian and U.K. launches of the Z10
have been the best of any of its handsets debuts in those regions ever. The
Z10 will not be in stores in the United States until an unspecified point in
March.

The Walt Disney Company (NYSE: DIS) - shares of DIS hit a new 52-week high of
$55.50 on Wednesday after the Company released positive first-quarter earnings
results. The company reported $0.79 earnings per share for the quarter,
beating the consensus estimate of $0.77 by $0.02. The company had revenue of
$11.34 billion for the quarter, compared to the consensus estimate of $11.21
billion. The Company's revenue was up 5.2% compared to the same quarter last
year. DIS was one of the most active stocks traded on the NYSE yesterday. The
Company also announced they will be expanding the Star Wars Franchise and will
create two Star Wars spinoffs.

Vocus Inc. (Nasdaq: VOCS) - Vocus Inc. was one of the biggest losers in the
Nasdaq yesterday, dropping 13.64% at the close. The stock closed at $15.32 but
went as low as $13.48 on Wednesday. VOCS traded 1,680,508 shares yesterday, a
big increase from its average of 129,069 shares. The Company had strong Q4
earnings, but issued discouraging guidance for 2013 including the year's first
quarter. For the first quarter, Vocus is projecting revenue of $46.3 million
to $46.7 million and non-GAAP profits of 9-10 cents a share; Street consensus
had been $49 million and 13 cents.

BIOLASE, Inc. (Nasdaq: BIOL) - BIOL shares saw a big boost on Wednesday
closing at $3.38, up $0.55 (19.43%). The stock hit a new 52-week high
yesterday of $3.93 on trading volume over three million shares compared to an
average of 98,519. The U.S. Food and Drug Administration (FDA) has cleared the
Company's 940nm Diolase 10 diode soft tissue laser for use in 19 additional
medical markets including: ear, nose and throat, oral surgery, arthroscopy,
gastroenterology, general surgery, dermatology, plastic surgery, podiatry,
GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac
surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular
surgery. BIOLASE, Inc. is the world's leading manufacturer and distributor of
dental lasers.

To find similar research reports that are available for free follow the link
below and sign up at http://www.TheStockFreak.com    

Disclosure: TheStockFreak.com is not a registered investment advisor and
nothing contained in any materials should be construed as a recommendation to
buy or sell securities. Investors should always conduct their own due
diligence with any potential investment. Please read our report and visit our
website, for complete risks and disclosures.

Contact: Contact: Info@thestockfreak.com, 433 plaza real Suite 275, Boca
Raton, Fl, 33432, +1-561-372-8342
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement